A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma

Br J Haematol. 2020 Dec;191(5):e103-e106. doi: 10.1111/bjh.17063. Epub 2020 Aug 30.
No abstract available

Keywords: TP53 aberration; chemoresistance; mantle cell lymphoma; mutation burden.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Cyclophosphamide / administration & dosage
  • Disease-Free Survival
  • Doxorubicin / administration & dosage
  • Female
  • Humans
  • Lymphoma, Mantle-Cell* / drug therapy
  • Lymphoma, Mantle-Cell* / genetics
  • Lymphoma, Mantle-Cell* / mortality
  • Male
  • Middle Aged
  • Mutation*
  • Prednisone / administration & dosage
  • Retrospective Studies
  • Survival Rate
  • Tumor Suppressor Protein p53 / genetics*
  • Vincristine / administration & dosage

Substances

  • TP53 protein, human
  • Tumor Suppressor Protein p53
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol